159992 创新药
已收盘 04-30 15:00:00
资讯
新帖
简况
每周股票复盘：健康元（600380）呼吸制剂结构优化创新药占比超35%
证券之星 · 03:48
每周股票复盘：健康元（600380）呼吸制剂结构优化创新药占比超35%
【券商聚焦】华源证券首予海西新药(02637)“买入”评级 指创新药HXP056有望打开估值空间
金吾财讯 · 04-30 16:45
【券商聚焦】华源证券首予海西新药(02637)“买入”评级 指创新药HXP056有望打开估值空间
核心产品放量带动业绩，创新药企股价集体走强
21世纪经济报道 · 04-30 14:53
核心产品放量带动业绩，创新药企股价集体走强
中国创新药出海，如何从“能出去”到 “走得远”？
中国新闻网 · 04-29 15:42
中国创新药出海，如何从“能出去”到 “走得远”？
东方证券：2026 ASCO盛会将至 中国创新药强势突围
智通财经 · 04-28
东方证券：2026 ASCO盛会将至 中国创新药强势突围
A股创新药板块逆势走强，创新药ETF易方达（516080）标的指数半日涨近2%
中金财经 · 04-28
A股创新药板块逆势走强，创新药ETF易方达（516080）标的指数半日涨近2%
百济神州(06160)与华辉安健签订《合作协议》引进三特异性创新药全球独家开发权益
智通财经 · 04-27
百济神州(06160)与华辉安健签订《合作协议》引进三特异性创新药全球独家开发权益
告别乙流多次服药！健康元创新药玛帕西沙韦胶囊或成更优选择
中金财经 · 04-25
告别乙流多次服药！健康元创新药玛帕西沙韦胶囊或成更优选择
【券商聚焦】申万宏源首予海西新药(02637)“买入”评级 指其大力推进创新药研发
金吾财讯 · 04-24
【券商聚焦】申万宏源首予海西新药(02637)“买入”评级 指其大力推进创新药研发
港股异动 | 凯莱英(06821)午后涨近6% 20亿元化学大分子创新药CDMO项目落地天津经开区
智通财经 · 04-24
港股异动 | 凯莱英(06821)午后涨近6% 20亿元化学大分子创新药CDMO项目落地天津经开区
创新药概念持续拉升 海西新药(02637)领涨12.77%、歌礼制药-B(01672)涨6.27%
金吾财讯 · 04-24
创新药概念持续拉升 海西新药(02637)领涨12.77%、歌礼制药-B(01672)涨6.27%
什么情况？港股通创新药突遭重挫，龙头领跌12%！520880放量跌4.51%连失多根均线，加仓还是离场？
新浪基金 · 04-24
什么情况？港股通创新药突遭重挫，龙头领跌12%！520880放量跌4.51%连失多根均线，加仓还是离场？
中国创新药“军团”领跑AACR年会
21世纪经济报道 · 04-24
中国创新药“军团”领跑AACR年会
东阳光药(06887)：三款创新药亮相2026年AACR年会展示肿瘤免疫与精准靶向治疗领域多元化管线布局
智通财经 · 04-23
东阳光药(06887)：三款创新药亮相2026年AACR年会展示肿瘤免疫与精准靶向治疗领域多元化管线布局
汇率逆风撞上关键药物销售额失色 罗氏卡在专利悬崖与创新药接力的十字路口
智通财经 · 04-23
汇率逆风撞上关键药物销售额失色 罗氏卡在专利悬崖与创新药接力的十字路口
港股异动 | 创新药概念全线走低 油价上涨压制降息空间 市场关注创新药投融资前景
智通财经 · 04-23
港股异动 | 创新药概念全线走低 油价上涨压制降息空间 市场关注创新药投融资前景
晚期乳腺癌创新药德达博妥单抗在华上市
新京报 · 04-22
晚期乳腺癌创新药德达博妥单抗在华上市
创新药赛道走势分化，港股通创新药ETF易方达（159316）全天净申购超1亿份
证券之星 · 04-22
创新药赛道走势分化，港股通创新药ETF易方达（159316）全天净申购超1亿份
创新药收入占比首破六成，恒瑞医药Q1营收81亿元，净利同增22%
华尔街见闻 · 04-22
创新药收入占比首破六成，恒瑞医药Q1营收81亿元，净利同增22%
广发基金罗国庆旗下广发中证创新药产业ETF一季报最新持仓，重仓药明康德
证券之星 · 04-22
广发基金罗国庆旗下广发中证创新药产业ETF一季报最新持仓，重仓药明康德
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.836,"timestamp":1777532592000,"preClose":0.838,"halted":0,"volume":688026526,"delay":0,"changeRate":-0.0024,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.002,"latestTime":"04-30 15:00:00","open":0.834,"high":0.844,"low":0.827,"amount":574000000,"amplitude":0.0203,"askPrice":0.836,"askSize":5506,"bidPrice":0.835,"bidSize":12966,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778031000000},"marketStatusCode":5,"adr":0,"adjPreClose":0.838,"symbolType":"fund","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":0.922,"lowLimit":0.754,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.280019,"marketValue":0,"turnoverRate":0,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-05-06。","floatMarketCap":0},"requestUrl":"/m/hq/s/159992","defaultTab":"news","newsList":[{"id":"2632695642","title":"每周股票复盘：健康元（600380）呼吸制剂结构优化创新药占比超35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632695642","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632695642?lang=zh_cn&edition=full","pubTime":"2026-05-02 03:48","pubTimestamp":1777664893,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，健康元报收于10.93元，较上周的10.83元上涨0.92%。健康元当前最新总市值199.96亿元，在化学制药板块市值排名24/150，在两市A股市值排名1080/5200。来自机构调研要点：保健品业务2025年同比增长超过37%，延续高增长态势。但呼吸板块呈现结构优化趋势，妥布霉素吸入溶液保持快速增长，创新药占呼吸板块收入比例已提升至35%以上，转型战略成效显现。保健品业务2025年同比增长超37%，保持强劲增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0046","159992","06978","BK1161","BK0114","BK0028","600380","BK1574","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631468969","title":"【券商聚焦】华源证券首予海西新药(02637)“买入”评级 指创新药HXP056有望打开估值空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2631468969","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631468969?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:45","pubTimestamp":1777538722,"startTime":"0","endTime":"0","summary":"报告指，公司正从传统仿制药商业化平台升级为“仿创一体化”药企，仿制药业务提供稳定现金流，创新管线HXP056有望打开中长期估值上限。业务亮点包括：1.创新药HXP056：为潜在首批口服治疗wAMD/DME/RVO的药物，全球尚无已获批的wAMD口服制剂。2025年仿制药收入结构中，海慧通占比50.29%，安必力占比27.94%。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/ZmY0OWUwYjc0ZDYzZDFkYzRkNWJlMTY3NjE5MjUxNjU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZmY0OWUwYjc0ZDYzZDFkYzRkNWJlMTY3NjE5MjUxNjU=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980352","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","159992","02637","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631500529","title":"核心产品放量带动业绩，创新药企股价集体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2631500529","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631500529?lang=zh_cn&edition=full","pubTime":"2026-04-30 14:53","pubTimestamp":1777531980,"startTime":"0","endTime":"0","summary":"4月30日早间开盘前，港股创新药龙头信达生物（1801.HK）披露2026年一季报。数据显示，报告期内公司产品收入录得38亿元，同比增长超过50%。强劲的业绩表现直接带动二级市场股价走高。截至4月30日午间休盘，信达生物收报88.75港元/股，涨幅达4.53%，总市值攀升至1539.98亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604303726369187.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604303726369187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK1161","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631562640","title":"中国创新药出海，如何从“能出去”到 “走得远”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2631562640","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631562640?lang=zh_cn&edition=full","pubTime":"2026-04-29 15:42","pubTimestamp":1777448569,"startTime":"0","endTime":"0","summary":"在全球医药创新的浪潮中，中国创新药正以前所未有的姿态登上世界舞台。2026年政府工作报告提出“推动创新药和医疗器械高质量发展”，为行业升级注入强劲动力。今年一季度，中国创新药对外授权交易额已接近去年全年五成，大额BD交易密集落地，行业发展迎来“开门红”。然而亮眼数据背后，行业挑战依旧突出：国内药企独立完成欧美注册、生产及商业化的自主出海模式仍较为稀缺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604293724360819.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604293724360819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1574","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630373078","title":"东方证券：2026 ASCO盛会将至 中国创新药强势突围","url":"https://stock-news.laohu8.com/highlight/detail?id=2630373078","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630373078?lang=zh_cn&edition=full","pubTime":"2026-04-28 15:56","pubTimestamp":1777362991,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东方证券发布研报称，近日，2026 ASCO标题公布，12项中国研究入选LBA，证明中国研究的质量已全面获得国际认可;双抗与ADC两大赛道领跑，确立中国在IO 2.0与ADC 2.0时代的全球领先地位，尤其是康方AK112登顶Plenary Session，标志着国产创新药的临床价值获全球最高学术认可。东方证券主要观点如下：事件近日，2026年ASCO会议标题正式公布，国产创新药的学术价值、临床价值与全球竞争力将会大幅提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK0028","159992","BK0188","BK0276","BK1147","BK1161","BK0183","BK1564","BK0012","600958","03958","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630632473","title":"A股创新药板块逆势走强，创新药ETF易方达（516080）标的指数半日涨近2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630632473","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630632473?lang=zh_cn&edition=full","pubTime":"2026-04-28 14:03","pubTimestamp":1777356199,"startTime":"0","endTime":"0","summary":"截至午间收盘，中证创新药产业指数上涨1.8%，恒生港股通创新药指数下跌0.5%，港股通创新药ETF易方达(159316，联接基金A/C：024328/024329)早盘净申购达1500万份。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/28/20260428666239.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/28/20260428666239.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260428/32183499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159982","159992","06978","BK1574","399300","516080","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393872","title":"百济神州(06160)与华辉安健签订《合作协议》引进三特异性创新药全球独家开发权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393872","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630393872?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:03","pubTimestamp":1777287828,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州 发布公告，2026 年 4 月 24 日，公司全资子公司百济神州广州与华辉安健签订了一份《合作协议》。此外，华辉安健同意在相关里程碑达成后，向百济神州广州支付其被百济神州广州授予相关知识产权许可的对价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1500","LU2328871848.SGD","ONC","BK4526","LU0588546209.SGD","BK1583","LU1251922891.USD","LU0307460666.USD","BK4585","BK1588","LU1770034418.SGD","BK4588","06160","LU1303224171.USD","LU1719994722.HKD","BK4139","BK0239","BK1161","06978","BK1574","159992","688235","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630875040","title":"告别乙流多次服药！健康元创新药玛帕西沙韦胶囊或成更优选择","url":"https://stock-news.laohu8.com/highlight/detail?id=2630875040","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630875040?lang=zh_cn&edition=full","pubTime":"2026-04-25 08:24","pubTimestamp":1777076695,"startTime":"0","endTime":"0","summary":"近期，全国流感活动持续攀升，乙型流感强势主导本轮流行季，对公众健康构成显著威胁。中国疾控中心近期发布的全国急性呼吸道传染病哨点监测数据显示，全国流感病毒检测阳性率连续几周上升，北方省份检测阳性率高于南方。 目前，据了解玛帕西沙韦胶囊已在各大主流医药电商平台上线，患者可便捷咨询购买，有效提升了药品可及性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangjuejin/20260425/32173558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0114","BK1574","BK0077","159992","BK0188","BK1161","BK0239","06978","BK0028","BK0046","600380"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629901508","title":"【券商聚焦】申万宏源首予海西新药(02637)“买入”评级 指其大力推进创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2629901508","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629901508?lang=zh_cn&edition=full","pubTime":"2026-04-24 14:42","pubTimestamp":1777012941,"startTime":"0","endTime":"0","summary":"金吾财讯 | 申万宏源发布研报指，首次覆盖海西新药 ，给予“买入”评级，目标价298.28港元。研报指出，海西新药是一家通过仿制药业务已连续5年实现盈利的创新药企业，2025年营业收入达到5.82亿元人民币，同比增长25%，净利润达1.77亿元，同比增长30%。在仿制药业务稳定盈利后，公司大力推进创新药研发。首发适应症骨肉瘤预计2026年上半年开展III期临床研究。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979900","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","000166","02637","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629974938","title":"港股异动 | 凯莱英(06821)午后涨近6% 20亿元化学大分子创新药CDMO项目落地天津经开区","url":"https://stock-news.laohu8.com/highlight/detail?id=2629974938","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629974938?lang=zh_cn&edition=full","pubTime":"2026-04-24 14:26","pubTimestamp":1777011981,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，凯莱英午后涨近6%，截至发稿，涨5.49%，报97.1港元，成交额4458.26万港元。公开数据显示，2025年凯莱英化学大分子CDMO板块实现营业收入10.28亿元，同比增长123.72%，成为公司增长最为迅速的业务单元。公司预计26年多肽PPQ项目将达4个且多肽固相合成产能将从25年底的4.5万升增至26年底的6.9万升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1328615791.USD","BK4585","BK1161","BK4588","BK1574","06821","CDMO","BK0132","159992","BK0239","BK1191","06978","BK4139","VXUS","002821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629894566","title":"创新药概念持续拉升 海西新药(02637)领涨12.77%、歌礼制药-B(01672)涨6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629894566","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629894566?lang=zh_cn&edition=full","pubTime":"2026-04-24 13:11","pubTimestamp":1777007494,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念午后集体持续拉升，截至发稿，海西新药 涨12.77%，歌礼制药-B涨6.27%，诺诚健华涨5.18%，信达生物涨4.10%，科伦博泰生物涨2.84%，亚盛医药-B涨2.79%。西南证券亦表示，医药生物行业近期表现虽相对疲软，估值溢价率有所下降，但行业整体仍保持一定韧性。其他生物制品、医疗研发外包和原料药等细分领域表现突出，显示出医药创新和产业链优势的持续释放。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979909","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","LU0196878994.USD","LU2328871848.SGD","BK1583","LU2242644610.SGD","HK0000165453.HKD","LU2097828557.USD","BK1161","BK1574","06855","159992","LU2488822045.USD","LU0455707207.USD","BK1515","02637","BK1191","06978","LU2097828474.EUR","09969","LU0502904849.HKD","LU2097828631.EUR","LU2097828714.EUR","01672","01801","06990","BK1589","LU2097828805.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629707860","title":"什么情况？港股通创新药突遭重挫，龙头领跌12%！520880放量跌4.51%连失多根均线，加仓还是离场？","url":"https://stock-news.laohu8.com/highlight/detail?id=2629707860","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629707860?lang=zh_cn&edition=full","pubTime":"2026-04-24 09:18","pubTimestamp":1776993480,"startTime":"0","endTime":"0","summary":"4月23日，港股继续调整，恒指放量连阴失守26000点。港股通创新药突遭急跌，100%创新药研发标的——港股通创新药ETF华宝收跌4.51%五连阴，失守10日、20日及半年线等3根均线。 值得关注的是，520880全天宽幅溢价，且交投尤为活跃，全天成交3.8亿元，较上日激增逾95%。 权重龙头多股重挫为主要拖累，前十成份股中仅石药集团逆市收涨1.71%，康方生物领跌12.66%，三生制药跌9.63%，信达生物、科伦博泰生物跌近6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-04-24/doc-inhvqfhn3227784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","06978","159992","BK4585","BK4588","VXUS","520880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629643518","title":"中国创新药“军团”领跑AACR年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2629643518","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629643518?lang=zh_cn&edition=full","pubTime":"2026-04-24 07:00","pubTimestamp":1776985200,"startTime":"0","endTime":"0","summary":"1907年的华盛顿，11位医生与科学家随手组建的“小圈子”，谁也没想到会演变成今天全球癌症研究领域最负盛名的盛会——美国癌症研究协会（AACR）。一百多年后的今天，AACR年会早已不只是一场学术会议，更是全球肿瘤研发的“晴雨表”和“风向标”。对中国生物医药产业而言，AACR也成为观察创新活力与国际化进程的最佳窗口。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604243716840281.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604243716840281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1161","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629880358","title":"东阳光药(06887)：三款创新药亮相2026年AACR年会展示肿瘤免疫与精准靶向治疗领域多元化管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2629880358","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629880358?lang=zh_cn&edition=full","pubTime":"2026-04-23 18:25","pubTimestamp":1776939928,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药 发布公告，于2026年4月17日至22日在美国加利福尼亚州圣地亚哥举行的 2026年美国癌症研究协会年会上，本集团以三份壁报形式集中展示了肿瘤治疗领域三款在研管线的最新临床前研究成果。上述三款创新药物在AACR年会上的集中亮相，不仅丰富了本集团的差异化产品管线，更展现了本集团在攻克不可成药靶点及开发下一代免疫疗法方面的技术积累与战略决心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","06887","BK1191","BK1574","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629034000","title":"汇率逆风撞上关键药物销售额失色 罗氏卡在专利悬崖与创新药接力的十字路口","url":"https://stock-news.laohu8.com/highlight/detail?id=2629034000","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629034000?lang=zh_cn&edition=full","pubTime":"2026-04-23 14:59","pubTimestamp":1776927545,"startTime":"0","endTime":"0","summary":"按固定汇率计算，总销售额则增长6%。其中制药业务销售额高达114.69亿瑞士法郎，占集团销售额的77.9%，诊断业务销售额32.53亿瑞士法郎，占22.1%。在上一季度曾经令投资者们失望的重磅眼科药物Vabysmo，第一季度实现销售额显著增长13%，并显示出在美国市场可能出现强劲复苏的迹象;此前，罗氏不得不加大资助力度，以帮助患者们获得该药物。罗氏股价今年以来已下跌近5%。罗氏股价今年以来疲软，本质上是市场在交易三重担忧。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","159992","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629023400","title":"港股异动 | 创新药概念全线走低 油价上涨压制降息空间 市场关注创新药投融资前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2629023400","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629023400?lang=zh_cn&edition=full","pubTime":"2026-04-23 13:59","pubTimestamp":1776923941,"startTime":"0","endTime":"0","summary":"消息面上，地缘局势不确定性持续存在，油价上涨推升通胀预期压制降息空间。招商银行研究院发布报告称，2025年，受到全球地缘政治压力以及美联储降息节奏的影响，全球创新药融资同比下降7.1%，但Q3的融资额已恢复8%的正增长。2026年如果美伊战争影响逐渐消除，美联储仍能持续降息，创新药投融资有望持续恢复。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["USL","DBE","BK1589","LU2097828805.USD","DRIP","LU2097828631.EUR","DRLL","BWET","01530","PXJ","OILU","LU2097828474.EUR","03692","IEO","LU1969619763.USD","UGA","VDE","BK1593","BNO","06978","BK4570","GUSH","BK1583","VXUS","BK1574","DUG","LU2097828714.EUR","159992","HK0000165453.HKD","IXC","LU0455707207.USD","DIG","LU2328871848.SGD","OILT","09995","DBO","LU2488822045.USD","BK1161","BK1191","LU2242644610.SGD","OIH","LU0502904849.HKD","USE","ERX","OILK","USOI","DBC","01801","LU2097828557.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629104691","title":"晚期乳腺癌创新药德达博妥单抗在华上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2629104691","media":"新京报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629104691?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:57","pubTimestamp":1776859020,"startTime":"0","endTime":"0","summary":"新京报讯（记者王卡拉）4月22日，阿斯利康与第一三共合作开发并引入中国的第二款抗体偶联药物（ADC）注射用德达博妥单抗（商品名：达卓优）在中国正式上市，首批到货将陆续在全国各地医院和药房落地启用。乳腺癌是中国女性最高发的恶性肿瘤之一，仅2022年确诊病例就超过35万例，并造成约7.5万例患者死亡。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604223714396528.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223714396528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1161","IPOS","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629204554","title":"创新药赛道走势分化，港股通创新药ETF易方达（159316）全天净申购超1亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2629204554","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629204554?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:45","pubTimestamp":1776858351,"startTime":"0","endTime":"0","summary":"4月22日，受市场影响，创新药赛道走势分化，港股创新药板块冲高回落低位震荡，A股创新药板块低开高走，截至收盘，恒生港股通创新药指数下跌0.6%，中证创新药产业指数上涨0.8%，资金逆势布局，港股通创新药ETF易方达(159316，联接基金A/C：024328/024329)全天净申购超1亿份。招银国际指出，生物医药产业定位跃升为新兴支柱产业，预示全链条政策红利将持续释放，AI制药技术突破与中国创新药出海BD爆发形成双重共振，行业基本面有望加速向好。当前国产创新药出海合作已从单一管线授权升级至平台层面合作，跨国药企对中国医药研发实力的认可度正系统性提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026042200048504.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159316","BK1574","159992","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629127880","title":"创新药收入占比首破六成，恒瑞医药Q1营收81亿元，净利同增22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629127880","media":"华尔街见闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629127880?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:22","pubTimestamp":1776853336,"startTime":"0","endTime":"0","summary":"恒瑞医药一季报显示，公司实现营收81.41亿元，同比增长12.98%；归母净利润22.82亿元，同比增长21.78%。创新药销售收入占比首次突破六成，达61.69%，其中非肿瘤产品收入同比增长92.13%，多元化趋势明显。报告期内累计研发投入22.24亿元，3项创新成果获批，8项新药上市申请获受理，管线推进节奏加快。","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3770612","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"创新药收入占比首破六成，恒瑞医药Q1营收81亿元，净利同增22%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600276","01276","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629506945","title":"广发基金罗国庆旗下广发中证创新药产业ETF一季报最新持仓，重仓药明康德","url":"https://stock-news.laohu8.com/highlight/detail?id=2629506945","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629506945?lang=zh_cn&edition=full","pubTime":"2026-04-22 07:14","pubTimestamp":1776813269,"startTime":"0","endTime":"0","summary":"证券之星消息，4月22日广发基金旗下罗国庆管理的广发中证创新药产业交易型开放式指数基金公布一季报，近1年净值增长率15.91%。与上一季度相比，该基金前十大重仓股新增信立泰；并对药明康德增仓222.76万股，为该基金第一大重仓股；艾力斯等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200013520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1997245094.SGD","LU2125910500.SGD","LU1934453819.USD","LU2045819591.USD","LU1808992512.USD","LU1979443071.USD","LU2328871848.SGD","159992","LU0456842615.SGD","LU2242644610.SGD","LU0052750758.USD","BK1141","02359","LU1969619763.USD","LU0708995583.HKD","06978","LU2495084118.USD","BK1574","LU2488822045.USD","LU0320764599.SGD","BK1161","LU1997245177.USD","LU0348766576.USD","603259","LU0348767384.USD","BK1576","LU1997244956.HKD","LU1046422090.SGD","BK0216","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777670610497,"stockEarnings":[{"period":"1week","weight":0.0097},{"period":"1month","weight":0.0195},{"period":"3month","weight":-0.0024},{"period":"6month","weight":-0.0933},{"period":"1year","weight":0.1405},{"period":"ytd","weight":0.006}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.0566},{"period":"3month","weight":-0.0014},{"period":"6month","weight":0.0398},{"period":"1year","weight":0.2541},{"period":"ytd","weight":0.0361}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}